Early efficacy of Endostar combined with chemoradiotherapy for advanced cervical cancers.
The aim of this study was to investigate the early outcome of Endostar combined with chemoradiotherapy for advanced cervical cancer. Fifty-two cases (FIGO IIb to IVa) were divided randomly into two groups, receiving chemoradiotherapy alone (CRT group) and Endostar combined with chemoradiotherapy (CRT+E group). For the patients in the CRT+E group, Endostar was administered daily with the dosage of 7.5 mg/m2, and cisplatin was administered weekly with the dosage of 20 mg/m2 during the radiation. The regimens lasted for 4 weeks with no difference in chemoradiotherapy between the two groups. The early outcome complete remission rate was 73.1%, partial remission rate was 23.1% and the total response rate was 96.2% in CRT+E group, a significnat improvement on the 34.6%, 42.3% and 76.9%, respectively, in the CRT group. One year survive rates were 100% and 84.6% in the CRT+E group and CRT groups, the difference being significant. Endostar combined with chemoradiotherapy can improve the early outcome of the advanced cervical cancer, and adverse effects were not encountered.
Department of Chemoradiotherapy, Oncology Hospital of Jingzhou, Jingzhou, China.
Qing-Hua
QH
Ke
Shi-Qiong
SQ
Zhou
Min
M
Huang
Yong
Y
Lei
Wei
W
Du
Ji-Yuan
JY
Yang
D000971:Antineoplastic Combined Chemotherapy Protocols; D059248:Chemoradiotherapy / Q000009:adverse effects; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use; D043169:Endostatins / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011994:Recombinant Proteins; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000628:therapy*
D043169:Endostatins; D011994:Recombinant Proteins; C522911:endostar protein; D002945:Cisplatin